Viela Bio is now part of Horizon Therapeutics. Learn More.

X
MENU
Patient Referral Form
Patient Referral Form

ACCESS AND SUPPORT

ACCESS AND SUPPORT

Viela VIPs: personal support for your patients

Viela VIPs is a patient support program for patients and care partners. The program offers a team of Nurse Case Managers and Reimbursement Case Managers who will provide:

  • One-on-one support
  • Help with insurance and coverage
  • Financial information and assistance
  • Educational resources

To get started, call
1-833-ViB-VIPs (1-833-842-8477) or go to
VielaVIPs.com.

Stay up-to-date on Uplizna

Get the latest on Uplizna® (inebilizumab-cdon)—sign up to stay informed:

Thank you for signing up to stay informed about Uplizna® (inebilizumab-cdon)! You’ll be the first to know about any product updates, news and more.

I wish to receive product and educational information from Viela Bio, its affiliate and service providers. I understand I can opt out at any time.

By clicking Register Now, I agree to the Viela Bio Privacy Policy and Legal Notice.

Older woman in scarf

Resources

Patient Referral Form

If you and your patient decide Uplizna® (inebilizumab-cdon) is right for them, complete this form with your patient to get them started—it will also serve as their prescription.

Download

Patient Referral Form Tip Sheet

Questions about the Patient Referral Form? This tip sheet may help.

Download

Efficacy and Safety

Uplizna as a monotherapy was proven to significantly reduce the risk of relapses that can cause permanent disability.

Explore the clinical study data
Patient resources

More Resources for Your Patients

Conversation guides and downloadable materials to help inform and educate your patients about Uplizna.

See patient resources
Two times a year

Twice-yearly Dosing With Uplizna

Uplizna is the only treatment for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year (after initial two start-up doses).

Get info about infusions
INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

Uplizna® (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

Uplizna is contraindicated in patients with:

  • A history of life-threatening infusion reaction to Uplizna
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: Uplizna can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by Uplizna-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay Uplizna administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining Uplizna with another immunosuppressive therapy.

The risk of hepatitis B virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with Uplizna. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in Uplizna clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold Uplizna and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Uplizna.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued Uplizna treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with Uplizna until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping Uplizna.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with Uplizna and greater than placebo) were urinary tract infection and arthralgia.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

Uplizna® (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

Uplizna is contraindicated in patients with:

  • A history of life-threatening infusion reaction to Uplizna
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: Uplizna can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by Uplizna-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay Uplizna administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining Uplizna with another immunosuppressive therapy.

The risk of hepatitis B virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with Uplizna. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in Uplizna clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold Uplizna and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Uplizna.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued Uplizna treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with Uplizna until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping Uplizna.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with Uplizna and greater than placebo) were urinary tract infection and arthralgia.